Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.

Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ.

Sci Transl Med. 2019 Mar 27;11(485). pii: eaau7746. doi: 10.1126/scitranslmed.aau7746.

PMID:
30918115
2.

Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation.

Gutiérrez-García G, Rovira M, Magnano L, Rosiñol L, Bataller A, Suárez-Lledó M, Cibeira MT, de Larrea CF, Garrote M, Jorge S, Moreno A, Rodríguez-Lobato LG, Carreras E, Díaz-Ricart M, Palomo M, Martínez C, Urbano-Ispizua A, Bladé J, Fernández-Avilés F.

Bone Marrow Transplant. 2018 Dec;53(12):1541-1547. doi: 10.1038/s41409-018-0189-2. Epub 2018 Apr 29.

PMID:
29706650
3.

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.

Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, Roué G, de Larrea CF.

Haematologica. 2017 Oct;102(10):1776-1784. doi: 10.3324/haematol.2017.164632. Epub 2017 Jul 27.

4.

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.

Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM, Teixidó M, Gimenez MT, Senín A, Sanz P, Campoy D, Vicent A, Arenillas L, Rosiñol L, Sierra J, Bladé J, de Larrea CF; GEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya).

Haematologica. 2017 Jun;102(6):1099-1104. doi: 10.3324/haematol.2016.158303. Epub 2017 Mar 2.

5.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID:
27956157
6.

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O.

Leuk Lymphoma. 2017 Mar;58(3):639-645. doi: 10.1080/10428194.2016.1214953. Epub 2016 Aug 9.

7.

At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study.

Martínez-Cibrian N, Magnano L, Gutiérrez-García G, Andrade X, Correa JG, Suárez-Lledó M, Martínez C, Rovira M, Carreras E, Rosiñol L, de Larrea CF, Cibeira MT, Gaya A, Gallego C, Hernando A, Creus N, Bladé J, Urbano-Ispizua Á, Fernández-Avilés F.

Bone Marrow Transplant. 2016 Apr;51(4):593-5. doi: 10.1038/bmt.2015.287. Epub 2015 Nov 23. No abstract available.

PMID:
26595072
8.

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.

Tovar N, de Larrea CF, Aróstegui JI, Cibeira MT, Rosiñol L, Rovira M, Elena M, Filella X, Yagüe J, Bladé J.

Haematologica. 2013 Jul;98(7):1142-6. doi: 10.3324/haematol.2013.084350. Epub 2013 May 3.

9.

Extramedullary involvement in multiple myeloma.

Bladé J, de Larrea CF, Rosiñol L.

Haematologica. 2012 Nov;97(11):1618-9. doi: 10.3324/haematol.2012.078519. No abstract available.

10.

Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.

Tovar N, Cibeira MT, Rosiñol L, Solé M, de Larrea CF, Escoda L, Rovira M, Bladé J.

Eur J Haematol. 2012 Oct;89(4):340-4. doi: 10.1111/j.1600-0609.2012.01821.x. Epub 2012 Jul 10.

PMID:
22690902
11.

Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.

de Larrea CF, Navarro A, Tejero R, Tovar N, Díaz T, Cibeira MT, Rosiñol L, Ferrer G, Rovira M, Rozman M, Monzó M, Bladé J.

Clin Cancer Res. 2012 Jul 1;18(13):3697-704. doi: 10.1158/1078-0432.CCR-12-0191. Epub 2012 Apr 26.

12.

Incorporating monoclonal antibodies into the therapy of multiple myeloma.

Bladé J, de Larrea CF, Rosiñol L.

J Clin Oncol. 2012 Jun 1;30(16):1904-6. doi: 10.1200/JCO.2011.40.4178. Epub 2012 Jan 30. No abstract available.

PMID:
22291081
13.

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.

Cibeira MT, de Larrea CF, Navarro A, Díaz T, Fuster D, Tovar N, Rosiñol L, Monzó M, Bladé J.

Leuk Res. 2011 Sep;35(9):1178-83. doi: 10.1016/j.leukres.2011.02.009. Epub 2011 Mar 23.

PMID:
21435719
14.

Cytoplasmic inclusions in leukocytes associated to cryoglobulinemia and IgG-kappa monoclonal gammapathy of undetermined significance.

Merino A, de Larrea CF, Bladé J.

Eur J Haematol. 2011 Jun;86(6):550. doi: 10.1111/j.1600-0609.2011.01584.x. Epub 2011 Mar 23. No abstract available.

PMID:
21306435
15.

How to treat multiple myeloma: thoughts on a multicentre survey in Germany.

Bladé J, Rosiñol L, Cibeira MT, de Larrea CF.

Onkologie. 2010;33(11):577-8. doi: 10.1159/000321564. Epub 2010 Oct 25. No abstract available.

16.

Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures.

De Larrea CF, Rosiñol L, Cibeira MT, Rozman M, Rovira M, Bladé J.

Eur J Haematol. 2010 Nov;85(5):448-51. doi: 10.1111/j.1600-0609.2010.01504.x.

PMID:
20964719
17.

Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition.

de Larrea CF, Cibeira MT, Elena M, Arostegui JI, Rosiñol L, Rovira M, Filella X, Yagüe J, Bladé J.

Blood. 2009 Dec 3;114(24):4954-6. doi: 10.1182/blood-2009-06-224832. Epub 2009 Oct 1.

18.

Use of anabolic-androgenic steroids masking the diagnosis of pleural tuberculosis: a case report.

de Larrea CF, Duplat A, Rivera-Olivero I, de Waard JH.

J Med Case Rep. 2009 Jan 28;3:30. doi: 10.1186/1752-1947-3-30.

19.

Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.

de Larrea CF, Cibeira MT, Vallansot R, Colomo L, Bladé J.

Clin Lymphoma Myeloma. 2008 Oct;8(5):312-4. doi: 10.3816/CLM.2008.n.045.

PMID:
18854288
20.

The effect of Bacille Calmette-Guérin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis.

Araujo Z, de Waard JH, de Larrea CF, Borges R, Convit J.

Vaccine. 2008 Oct 16;26(44):5575-81. doi: 10.1016/j.vaccine.2008.08.006. Epub 2008 Aug 22.

PMID:
18723065
21.

Pathogenesis and progression of monoclonal gammopathy of undetermined significance.

Bladé J, Rosiñol L, Cibeira MT, de Larrea CF.

Leukemia. 2008 Sep;22(9):1651-7. doi: 10.1038/leu.2008.203. Epub 2008 Jul 31. Review.

PMID:
18668131
22.

The secretory immunoglobulin A response to Mycobacterium tuberculosis in a childhood population.

de Larrea CF, de Waard JH, Giampietro F, Araujo Z.

Rev Soc Bras Med Trop. 2006 Sep-Oct;39(5):456-61.

Supplemental Content

Loading ...
Support Center